In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.

Author: Maulrajas Zujora
Country: Kazakhstan
Language: English (Spanish)
Genre: History
Published (Last): 24 December 2006
Pages: 83
PDF File Size: 9.24 Mb
ePub File Size: 11.90 Mb
ISBN: 834-7-83321-930-7
Downloads: 85064
Price: Free* [*Free Regsitration Required]
Uploader: Mikakora

The reasons that VKA therapy was unsuitable for the patient had to be documented in the study case report forms.

The New England Journal of Medicine. Mortality rates were 3.

This proportion was similar for both academic and community hospitals. AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. Apixsban a mean follow-up of 1. VKA therapy not recommended by the physician; J Am Coll Cardiol ; Connolly SJ, et al.


AVERROES – Wiki Journal Club

N Engl J Med To reduce the burden of cardiovascular disease. Apixaban in Patients with Atrial Fibrillation. Guidelines for the management of atrial xverroes Eur Heart J ; This page was last modified on 3 Decemberat Based on the indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs.

Analyses are to time of first event. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin avergoes patients with atrial fibrillation according to stroke risk: One may question each of these choices: In such patients, aspirin plus clopidogrel reduced the rate of major vascular events, in particular stroke, vs.

N Engl J Med ; Patients also needed to have at least one of the following risk factors for stroke: Expected difficulty in contacting patient for urgent change in dose of VKAs; 6.

Presented as apixaban vs. Its role in prevention of stroke in patients unsuitable for VKA therapy, but maintained on aspirin therapy, was unknown.

The AVERROES Trial – Clinical Implications

A serious bleeding event during VKA therapy; 4. ESC sub specialties communities. Retrieved from ” http: Read your latest personalised notifications Sign in No account yet?


Dual therapy decreased rates of major vascular events at cost of increased major bleeding. Also, how does apixaban compare to aspirin rates of major bleeding?

There were 11 intracranial bleeds on apixaban and 13 on aspirin apixaban 1.

The median duration of follow-up was 1. Concurrent medications that could alter activity of VKAs; 8.

Views Read View source View history. Notes to editor Correspondence: Apixaban is a novel oral anticoagulant that inhibits factor Xa.

The AVERROES Trial – Clinical Implications

Adverse event not related to bleeding during VKA therapy; 3. Thus, a clear superiority of apixaban over aspirin was shown in terms of efficacy, with comparable safety. Don’t miss out Read your latest personalised notifications Averrroes, got it.